Sanofi’s BTK inhibitor meets primary endpoint in Phase 2b to treat MS
Category: #health  By Saipriya Iyer  Date: 2020-02-08
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sanofi’s BTK inhibitor meets primary endpoint in Phase 2b to treat MS

MS (multiple sclerosis) is a serious disease that affects about 1.2 million people across the U.S. and Europe. The ailment is a chronic disease that attacks the CNS (central nervous system). Today, despite present therapies, several MS patients continue to face disability, with one in four of the MS patients suffering from a progressive forms of this disease with no treatments or very limited treatments available. Global pharmaceutical companies are working diligently to find a cure.

A recent effort in this regard came to light when Sanofi, a renowned French pharmaceutical company, reportedly announced that its investigational BTK inhibitor achieved its primary endpoint in the Phase 2b trial. The company’s Bruton's tyrosine kinase (BTK) inhibitor (SAR442168) is a brain-penetrant, oral, and selective small-molecule developed to address multiple sclerosis.

In the Phase 2b study, the BTK inhibitor significantly decreased the disease activity associated with MS, as per measurements done using MRI (magnetic resonance imaging). SAR442168 inhibitor was well tolerated along with no novel safety findings.

The SAR442168 is considered to modulate both innate (CNS microglial cells) and adaptive (B-cell activation) immune cells associated with neuroinflammation in the spinal cord and brain. 

Sanofi’s Global Head of Research and Development, John Reed, M.D., Ph.D. stated that majority of people suffering from MS still endure disability in the course of this disease. The company believes that its BTK inhibitor has the ability to change how multiple sclerosis is treated. This inhibitor might be the first B-cell-targeted MS treatment that hinders the peripheral immune system and crosses the blood-brain barrier to block immune cells that have moved to the brain, while modulating the brain-resident microglia cells which are being implicated in micro sclerosis progression as well.  

Reed further added that building on the company’s heritage in MS, the company is thrilled by these clinical outcomes and looks forward to advance its brain penetrant SAR442168 inhibitor into pivotal clinical studies.

Four Phase 3 studies would further investigate the SAR442168 inhibitor’s effect on multiple sclerosis relapse rates, underlying CNS (central nervous system) damage, and disability progression. Phase 3 studies in progressive and relapsing forms of the MS are scheduled to start during the mid-2020.

Source credit: https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-06-07-00-00



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Copper3D unveils antimicrobial device to curb HIV risk via breastmilk
Copper3D unveils antimicrobial device to curb HIV risk via breastmilk
By Saipriya Iyer

Copper3D, a Chile- and U.S.-based antibacterial solutions provider, has recently worked on a project to create an antibacterial 3D printed device to mitigate the risk of HIV transmission during breastfeeding. The compa...

Tetra commences PoC clinical trial of PPP003v for companion dogs
Tetra commences PoC clinical trial of PPP003v for companion dogs
By Saipriya Iyer

Tetra Bio-Pharma Inc., a Canadian pharmaceutical firm that specializes in cannabinoid-derived drug therapy, has recently initiated a clinical study of synthetic cannabinoid therapy (PPP003v) for ophthalmic eye pain in ...

Satipharm begins clinical trial of CBD capsules for treating menopause
Satipharm begins clinical trial of CBD capsules for treating menopause
By Saipriya Iyer

Cannabis was prior considered to possess various medicinal benefits for treating diseases. However, after years of restriction, the scientific community is finally exploring the medical avenues of CBD by conducting adv...